P1.190. Residual Disease Subgroups and Survival After Trimodality Therapy for Esophageal Squamous Cell Carcinoma - Observational Study

Le résumé fourni par la source

Abstract Topic Esophageal Cancer: Surgical Treatment of Esophageal Cancer – early outcomes and complications Background For locally advanced oesophageal squamous cell carcinoma (ESCC) managed with trimodality therapy, the prognostic significance of different patterns of residual disease within the non-pathological complete response (non-pCR) population remains incompletely defined. This study applied a four-group pathological response classification to evaluate whether the anatomical distribution of residual disease — at the primary site, at regional lymph nodes, or at both — differentially determines disease-free and overall survival. Methods This retrospective, observational cohort study included 187 consecutive patients with ESCC who underwent neoadjuvant concurrent chemoradiotherapy (nCRT) followed by curative-intent oesophagectomy India, between 2021 and 2026. Patients were classified into four mutually exclusive groups: pCR+ (ypT0N0; n=91, 48.7%); Local Residual Disease (LRD: ypT≥1, ypN0; n=53, 28.3%); Nodal Residual Only (NRO: ypT0, ypN+; n=13, 7.0%); and combined Local and Nodal Residual Disease (LRD+NRO: ypT≥1, ypN+; n=30, 16.0%). Primary endpoints were disease-free survival (DFS) and overall survival (OS). Groups were compared by Kaplan–Meier analysis with Bonferroni-corrected pairwise log-rank tests. Independent prognostic determinants were identified by multivariable Cox proportional hazards regression with LRD+NRO as the reference category. Results The four groups differed significantly in observed survival at last follow-up (p<0.001): alive rates were 79.5% (pCR+), 76.1% (LRD), 100% (NRO; exploratory, n=13), and 47.8% (LRD+NRO). Estimated three-year OS was approximately 80%, 72%, 85%, and 42%, respectively. On multivariable analysis, pCR+ was independently associated with significantly better DFS (adjusted hazard ratio [aHR] 0.38, 95% CI 0.21–0.68; p<0.001) and OS (aHR 0.41; p<0.001) versus LRD+NRO. LRD was also independently associated with improved DFS versus LRD+NRO (aHR 0.55, 95% CI 0.30–1.00; p=0.049). R1 resection margin was independently associated with worse DFS (aHR 1.83; p=0.036). The NRO result was non-significant (aHR 0.62; p=0.32), likely reflecting limited power (n=13). Conclusion Combined local and nodal residual disease (LRD+NRO) confers the worst prognosis following trimodality therapy for ESCC. The four-group classification provides granular prognostic stratification beyond binary pCR assessment and has direct implications for adjuvant therapy planning and post-operative surveillance intensity. Prospective validation in larger cohorts is warranted, with particular focus on the NRO subgroup.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.